世界の癌治療用ジェネリック医薬品市場

◆英語タイトル:Global Cancer Generics Market Outlook 2018
◆商品コード:RNCS4087
◆発行会社(調査会社):RNCOS
◆発行日:2014年8月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,400 ⇒換算¥142,800見積依頼/購入/質問フォーム
Multi-UserUSD2,000 ⇒換算¥204,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.

According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.

Our report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.

Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. Global Cancer Generics Market Analysis 2018
5. Cancer Generic Drugs Industry
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. Cancer Generics Market: Major Indications
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. Market Dynamics
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. Key Players
8.1 Fresenius Kabi AG
8.1.1 Business Overview
8.1.2 Key Financials
8.1.3 Strategic Developments
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Key Financials
8.2.3 Strategic Developments
8.3 Hospira
8.3.1 Business Overview
8.3.2 Key Financials
8.3.3 Strategic Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Business Overview
8.4.2 Key Financials
8.4.3 Strategic Developments
8.5 Mylan
8.5.1 Business Overview
8.5.2 Key Financials
8.5.3 Strategic Developments
8.6 Sun Pharmaceuticals
8.6.1 Business Overview
8.6.2 Key Financials
8.6.3 Strategic Developments

List of Figures:

Figure 3-1: Global – Number of New Cancer Cases (Million), 2012 & 2025
Figure 3-2: Global – Cancer Incidences by Gender (Million), 2012
Figure 3-3: Global – Cancer Drugs Market (Billion US$), 2008-2013
Figure 3-4: Global – Cancer Drugs Market (Billion US$), 2014-2018
Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
Figure 3-7: Global – Cancer Treatment Modalities Revenue Share (%), 2013
Figure 4-1: Global – Cancer Generics Market (Billion US$), 2013-2018
Figure 6-1: Global – Number of New Lung Cancer Cases (Million), 2012 & 2020
Figure 6-2: Global – Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-3: Global – Number of New Breast Cancer Cases (Million), 2012 & 2020
Figure 6-4: Global – Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-5: Global – Number of New Colorectal Cancer Cases (Million), 2012 & 2020
Figure 6-6: Global – Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-7: Global – Number of New Stomach Cancer Cases (Million), 2012 & 2020
Figure 6-8: Global – Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-9: Global – Number of New Prostate Cancer Cases (Million), 2012 & 2020
Figure 6-10: Global – Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 8-1: Fresenius Kabi – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-2: Fresenius Kabi – Revenue Share by Region (%), 2013
Figure 8-3: Fresenius Kabi – Revenue Share by Business Segment (%), 2013
Figure 8-4: Actavis – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-5: Actavis – Revenue Share by Region (%), 2013
Figure 8-6: Actavis – Revenue Share by Business Segment (%), 2013
Figure 8-7: Hospira – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-8: Hospira – Revenue Share by Region (%), 2013
Figure 8-9: Hospira – Revenue Share by Business Segment (%), 2013
Figure 8-10: Teva – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-11: Teva – Revenue Share by Region (%), 2013
Figure 8-12: Hospira – Revenue Share by Business Segment (%), 2013
Figure 8-13: Mylan – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-14: Mylan – Revenue Share by Region (%), 2013
Figure 8-15: Mylan – Revenue Share by Business Segment (%), 2013
Figure 8-16: Sun Pharma – Sales & Net Income (Billion US$), 2012-13/ 2013-14
Figure 8-17: Sun Pharma – Revenue Share by Business Segment (%), 2013-14

List of Tables:

Table 3-1: Most Prevalent Types of Cancer
Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
Table 5-1: List of Companies Dealing in Generic Arimidex
Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 5-3: List of Companies Dealing in Generic Femara
Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 5-5: List of Companies Dealing in Generic Hycamtin
Table 5-6: List of Companies Dealing in Generic Xeloda
Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 5-8: List of Companies Dealing in Generic Camptosar
Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
Table 6-2: Global – Key Lung Cancer Drugs and Patent Expiry Status
Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
Table 6-4: Global – Key Breast Cancer Drugs and Patent Expiry Status
Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
Table 6-6: Global – Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
Table 6-8: Global – Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
Table 6-10: Global – Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: Global – Key Cancer Drugs and Patent Expiry Status
Table 8-1: Fresnius Kabi Pharmaceuticals – Key Cancer Generic Drugs
Table 8-2: Actavis – Key Cancer Generic Drugs
Table 8-3: Hospira – Key Cancer Generic Products
Table 8-4: Teva Pharmaceuticals – Key Cancer Generic Drugs
Table 8-5: Mylan – Key Cancer Generic Drugs
Table 8-6: Sun Pharmaceuticals – Key Cancer Generic Drugs



【レポートのキーワード】

癌、治療薬、ジェネリック医薬品、抗がん剤、肺癌、乳癌、結腸直腸癌、胃癌、薬

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界の癌治療用ジェネリック医薬品市場]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年06月29日現在 193,799 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆